News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,582 Results
Type
Article (39709)
Company Profile (311)
Press Release (651562)
Section
Business (204915)
Career Advice (2012)
Deals (35492)
Drug Delivery (91)
Drug Development (81072)
Employer Resources (168)
FDA (16154)
Job Trends (14873)
News (346073)
Policy (32575)
Tag
Academia (2551)
Alliances (49569)
Alzheimer's disease (1268)
Approvals (16114)
Artificial intelligence (146)
Bankruptcy (354)
Best Places to Work (11613)
Biotechnology (218)
Breast cancer (190)
Cancer (1377)
Cardiovascular disease (110)
Career advice (1679)
Cell therapy (283)
Clinical research (64847)
Collaboration (487)
Compensation (262)
COVID-19 (2557)
C-suite (110)
Data (1392)
Diabetes (177)
Diagnostics (6197)
Earnings (85050)
Employer resources (146)
Events (110582)
Executive appointments (399)
FDA (16844)
Funding (434)
Gene therapy (195)
GLP-1 (603)
Government (4347)
Healthcare (18732)
Infectious disease (2650)
Inflammatory bowel disease (115)
Interviews (310)
IPO (16380)
Job creations (3661)
Job search strategy (1431)
Layoffs (423)
Legal (7899)
Lung cancer (198)
Manufacturing (208)
Medical device (13247)
Medtech (13252)
Mergers & acquisitions (19278)
Metabolic disorders (462)
Neuroscience (1592)
NextGen Class of 2024 (6541)
Non-profit (4481)
Northern California (1704)
Obesity (262)
Opinion (188)
Parkinson's disease (98)
Patents (120)
People (56806)
Phase I (20198)
Phase II (28568)
Phase III (21273)
Pipeline (514)
Postmarket research (2561)
Preclinical (8578)
Radiopharmaceuticals (236)
Rare diseases (264)
Real estate (5938)
Regulatory (21757)
Research institute (2320)
Resumes & cover letters (351)
Southern California (1474)
Startups (3616)
United States (15292)
Vaccines (566)
Weight loss (183)
Date
Today (126)
Last 7 days (574)
Last 30 days (2380)
Last 365 days (35412)
2024 (35256)
2023 (40196)
2022 (51308)
2021 (55860)
2020 (54181)
2019 (46670)
2018 (35162)
2017 (32250)
2016 (31662)
2015 (37738)
2014 (31490)
2013 (26547)
2012 (28827)
2011 (29476)
2010 (27562)
Location
Africa (717)
Arizona (196)
Asia (37524)
Australia (6151)
California (3850)
Canada (1458)
China (308)
Colorado (173)
Connecticut (178)
Europe (80469)
Florida (537)
Georgia (137)
Illinois (393)
Indiana (226)
Maryland (635)
Massachusetts (2981)
Michigan (175)
Minnesota (291)
New Jersey (1108)
New York (1092)
North Carolina (746)
Northern California (1704)
Ohio (148)
Pennsylvania (930)
South America (1097)
Southern California (1474)
Texas (558)
Utah (108)
Washington State (402)
691,582 Results for "pulse biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
December 19, 2024
·
1 min read
Deals
Pulse Biosciences, Inc. Announces Commencement of Rights Offering - June 4, 2024
Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).
June 4, 2024
·
7 min read
Press Releases
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery
December 17, 2024
·
6 min read
Business
Pulse Biosciences Enhances Executive Leadership Team
Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced enhancements to its executive leadership team to support its next pivotal phase of growth.
May 14, 2024
·
7 min read
Biotech Bay
Pulse Biosciences Announces Plans to Initiate a Rights Offering
Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced that its Board of Directors has unanimously approved plans to initiate a rights offering.
March 28, 2024
·
5 min read
Business
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024.
May 7, 2024
·
13 min read
Biotech Bay
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
Pulse Biosciences, Inc. today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
May 16, 2024
·
5 min read
Biotech Bay
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
Pulse Biosciences, Inc. today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed.
May 9, 2024
·
6 min read
Biotech Bay
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering, which will be available to all holders of record of the Company’s common stock, par value $0.001 per share, now as of the close of the market on Friday, May 31, 2024.
May 20, 2024
·
6 min read
Press Releases
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
October 31, 2024
·
5 min read
1 of 69,159
Next